Literature DB >> 20804664

Non-traumatic osteonecrosis of the femoral head - from clinical to bench.

Mel S Lee1, Pang-Hsin Hsieh, Chun-Hsiung Shih, Ching-Jen Wang.   

Abstract

Non-traumatic osteonecrosis of the femoral head commonly affects young adults between the third and fifth decade of life. It is the leading cause of hip joint replacements in many Asian countries including Taiwan. The ultimate goal is the preservation of the involved hip. However, this is often challenging since early diagnosis is difficult, the etiologies are miscellaneous, the pathogenesis is unclear, and successful treatment is undetermined. As a consequence, this disease remains well-known but not fully-understood. This review provides an update of the progress from clinical studies to basic bench work in terms of natural history, risk factors, genetic predilections, diagnosis, staging, and miscellaneous therapeutic modalities.

Entities:  

Mesh:

Year:  2010        PMID: 20804664

Source DB:  PubMed          Journal:  Chang Gung Med J        ISSN: 2072-0939


  16 in total

1.  Effect of bone mesenchymal stem cells transplantation on the micro-environment of early osteonecrosis of the femoral head.

Authors:  Huanjin Song; Li Tao; Fang Wang; Weizhuo Wang; Yongchang Wei; Wenjun Shen; Fuling Zhou
Journal:  Int J Clin Exp Pathol       Date:  2015-11-01

2.  MicroRNA-mediated interacting circuits predict hypoxia and inhibited osteogenesis of stem cells, and dysregulated angiogenesis are involved in osteonecrosis of the femoral head.

Authors:  Gour-Shenq Kao; Yuan-Kun Tu; Pei-Hsun Sung; Feng-Sheng Wang; Yu-Der Lu; Chen-Ta Wu; Rio L C Lin; Hon-Kan Yip; Mel S Lee
Journal:  Int Orthop       Date:  2018-04-26       Impact factor: 3.075

3.  Long-term outcomes of Phemister bone grafting for patients with non-traumatic osteonecrosis of the femoral head.

Authors:  Cheng-Ta Wu; Shih-Hsiang Yen; Po-Chun Lin; Jun-Wen Wang
Journal:  Int Orthop       Date:  2018-06-18       Impact factor: 3.075

4.  The effects of autologous bone marrow mesenchymal stem cell arterial perfusion on vascular repair and angiogenesis in osteonecrosis of the femoral head in dogs.

Authors:  Hongting Jin; Bingjiang Xia; Nanze Yu; Bangjian He; Yan Shen; Luwei Xiao; Peijian Tong
Journal:  Int Orthop       Date:  2012-10-13       Impact factor: 3.075

5.  What is the pain source? A case report of a patient with low back pain and bilateral hip osteonecrosis.

Authors:  Amy L Minkalis; Robert D Vining
Journal:  J Can Chiropr Assoc       Date:  2015-09

6.  Increased risk of revision in patients with non-traumatic femoral head necrosis.

Authors:  Camilla Bergh; Ann M Fenstad; Ove Furnes; Göran Garellick; Leif I Havelin; Søren Overgaard; Alma B Pedersen; Keijo T Mäkelä; Pekka Pulkkinen; Maziar Mohaddes; Johan Kärrholm
Journal:  Acta Orthop       Date:  2013-12-20       Impact factor: 3.717

7.  Single nucleotide polymorphisms other than factor V Leiden are associated with coagulopathy and osteonecrosis of the femoral head in Chinese patients.

Authors:  Kou-Ti Peng; Kuo-Chin Huang; Tsan-Wen Huang; Yun-Shien Lee; Wei-Hsiu Hsu; Robert W W Hsu; Steve W N Ueng; Mel S Lee
Journal:  PLoS One       Date:  2014-08-13       Impact factor: 3.240

8.  Fast sequences MR imaging at the investigation of painful skeletal sites in patients with hip osteonecrosis.

Authors:  Aristidis H Zibis; Sokratis E Varitimidis; Zoe H Dailiana; Apostolos H Karantanas; Dimitrios L Arvanitis; Konstantinos N Malizos
Journal:  Springerplus       Date:  2015-01-06

9.  Diagnostic value of necrotic lesion boundary in bone collapse of femoral head osteonecrosis.

Authors:  Yinuo Fan; Jiahao Zhang; Minghai Chen; Fengxiang Pang; Haicheng Chen; Yulong Wu; Yupeng Liang; Zhiming Wei; Kaishen Cai; Weifeng Li; Hanjun Fang; Guoju Hong; Chi Zhou; Zhenqiu Chen
Journal:  Int Orthop       Date:  2021-05-27       Impact factor: 3.075

10.  High-Energy Extracorporeal Shock Wave for Early Stage Osteonecrosis of the Femoral Head: A Single-Center Case Series.

Authors:  Fuqiang Gao; Wei Sun; Zirong Li; Wanshou Guo; Weiguo Wang; Liming Cheng; Bailiang Wang
Journal:  Evid Based Complement Alternat Med       Date:  2015-11-02       Impact factor: 2.629

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.